Back to Results

Prothena Corporation plc (PRTA)

-


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-PRTA
$10.99
36.9% Upside
Undervalued
$21.40
166.5% Upside
Bargain
Good
0.0%
October 29, 2026
1.5x
7.6x
424.6 M
135.1 M
1.7%
67.3%
12.8
138.0%
Valuation • Fair Value

Prothena Corporation plc (NASDAQ-PRTA) Fair Value by Valuation Model

Review the available estimates for Prothena Corporation plc (NASDAQ-PRTA), including DCF Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$10.99

Estimated upside of 36.9% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$16.19

Discounted cash flow valuation reference.

EPV Fair Value

$11.29

Earnings power value estimate.

Comps Fair Value

$10.07

Comparable-company valuation reference.

Analyst Price Target

$21.40

Analysts imply upside of 166.5%.

How to read these valuation models

Use the 6 available valuation references for Prothena Corporation plc (NASDAQ-PRTA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Prothena Corporation plc (NASDAQ-PRTA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

54.53 M

Current operating scale indicator.

Revenue Forecast

89.25 M

Forward revenue estimate.

EBITDA

-59.04 M

Current operating profitability reference.

EBITDA Forecast

-355.7 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Prothena Corporation plc (NASDAQ-PRTA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Prothena Corporation plc (NASDAQ-PRTA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Altman Z-Score

12.8

Relatively strong balance-sheet zone.

FCF / Net Income

138.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Prothena Corporation plc (NASDAQ-PRTA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Prothena Corporation plc (NASDAQ-PRTA)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 29, 2026

Days to Earnings

23

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Prothena Corporation plc (NASDAQ-PRTA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Prothena Corporation plc (NASDAQ-PRTA) Stock Forecast & Technical Outlook

Review Prothena Corporation plc (NASDAQ-PRTA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Prothena Corporation plc (NASDAQ-PRTA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Prothena Corporation plc (NASDAQ-PRTA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Prothena Corporation plc (NASDAQ-PRTA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Prothena Corporation plc (NASDAQ-PRTA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Prothena Corporation plc (NASDAQ-PRTA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Prothena Corporation plc (NASDAQ-PRTA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Prothena Corporation plc (NASDAQ-PRTA) has a Hold consensus, with 1 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 2
Sell 0
FAQ • Fast Investor Answers

Prothena Corporation plc (NASDAQ-PRTA) Stock FAQ

Data-supported answers about Prothena Corporation plc (NASDAQ-PRTA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$10.99
Estimated upside 36.9%
Valuation Rating
Undervalued
Estimated upside of 36.9%
Analyst Target
$21.40
Implied upside 166.5%
Financial Health
Good
Current financial-health read

The current fair value estimate for Prothena Corporation plc (NASDAQ-PRTA) is $10.99. This implies an estimated upside of 36.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 36.9% versus the current market price.

The available analyst price target for Prothena Corporation plc (NASDAQ-PRTA) is $21.40. The analyst target implies estimated upside of 166.5%.

The current financial health read for Prothena Corporation plc (NASDAQ-PRTA) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Prothena Corporation plc (NASDAQ-PRTA) is October 29, 2026.

The latest available data indicates no current dividend yield for Prothena Corporation plc (NASDAQ-PRTA).

The current market capitalization listed for Prothena Corporation plc is 424.6 M.

The current enterprise value listed for Prothena Corporation plc is 135.1 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Prothena Corporation plc is NASDAQ-PRTA, and the stock is listed on NASDAQ.

Prothena Corporation plc (NASDAQ-PRTA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Prothena Corporation plc is 1.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Prothena Corporation plc is 67.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 469.6 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 217.9 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 179.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 127.6 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 81.129 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Bargain Market Cap 72.542 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 61.354 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 57.124 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Overvalued Market Cap 44.513 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.12 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.036 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 29.423 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 25.845 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.528 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 23.134 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 23.007 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 22.675 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 21.365 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 14.975 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.659 B